ResearcherThe Netherlands Cancer InstituteActive in the last 2 years

Antonio Mulero‐Sánchez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1668-7022; OpenAlex author ID A5047045246. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer. Co-author DOI 10.1186/s13046-025-03616-z ↗
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. First author DOI 10.1016/j.xcrm.2022.100815 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

René Bernards · 2 shared papers, 2022–2026 · strength 0.39
- Paper CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic ca… DOI 10.1186/s13046-025-03616-z ↗
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Sara Mainardi · 2 shared papers, 2022–2026 · strength 0.39
- Paper CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic ca… DOI 10.1186/s13046-025-03616-z ↗
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Wolfgang Weber · 1 shared paper, 2022 · strength 0.11
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Katrin J. Frank · 1 shared paper, 2022 · strength 0.11
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Marina Lesina · 1 shared paper, 2022 · strength 0.11
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Kıvanç Görgülü · 1 shared paper, 2022 · strength 0.11
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Derya Kabacaoğlu · 1 shared paper, 2022 · strength 0.11
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Dietrich Alexander Ruess · 1 shared paper, 2022 · strength 0.11
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Bruno Sáinz · 1 shared paper, 2022 · strength 0.11
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗
Hana Algül · 1 shared paper, 2022 · strength 0.11
- Paper Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pan… DOI 10.1016/j.xcrm.2022.100815 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.